VivoSeq
Other

Pancreatic Exocrine Insufficiency

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Pancreatic Exocrine Insufficiency is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

17/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed5 · 83%
Withdrawn1 · 17%

Clinical Trials

Trial Activity

6 trials

A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency
Completed·AAbbott·Phase 3·NCT00401076·80 enrolled
Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
Completed·—·Phase 3·NCT01747330·40 enrolled
Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
Completed·MMylan Inc.·N/A·NCT01427725·579 enrolled
BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency
Completed·MMeridian Bioscience, Inc.·Phase 2·NCT01259544·33 enrolled
A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency
Completed·AAbbott·Phase 3·NCT00400842·274 enrolled
Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency
Withdrawn·—·N/A·NCT01094600

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)